TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00954499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulation added to Standard care
Description: * Parent rubs the infant's skin near the injection site just before, during and after the injection.~* Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: * Fast injection technique without aspiration.~* Oral sucrose 2 minutes before first injection.~* Parent holds infant close.
Study: NCT03875742

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultraplex 360(Braun)
Description: This group will use as first needle the ultraplex 360 (Braun)

Intervention type: DEVICE
Group type: OTHER
Intervention: STIMUPLEX D SH, 30°(Braun)
Description: This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)
Study: NCT01542710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganfort
Description: Bimatoprost/Timolol fixed combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duotrav
Description: Fixed combination of Travoprost and Timolol
Study: NCT00258817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (Fluzone®)
Description: 0.25 mL, Intramuscular (Day 0 and Day 28)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (Fluzone®)
Description: 0.25 mL, Intramuscular (Day 0)
Study: NCT04043442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P
Description: rTMS device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P
Description: rTMS device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P
Description: rTMS device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P
Description: rTMS device
Study: NCT02243735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric(III)carboxymaltose
Description: Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
Study: NCT04102527

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients have to complete the study questionnaires every 2 months :~* Digestive Functional Score of Neurological Patients~* Bowel Function Index~* Severity score for constipation~* Bristol Scale~* Constipation assessment scale~* Estimate scale of risk of constipation
Study: NCT04096287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNT001
Description: PNT001 diluted in 5% dextrose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose
Study: NCT01593592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: All patients will receive omeprazole 20 mg b.i.d for 2 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: All patients will receive omeprazole 20 mg b.i.d for 2 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin
Description: amoxicillin 1000 mg b.i.d for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: amoxicillin 1000 mg b.i.d for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clarithromycin
Description: clarithromycin 500mg b.i.d for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: clarithromycin 500mg b.i.d for 2 weeks
Study: NCT00644488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-641988 (AR#2)
Description: Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
Study: NCT02474602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Description: Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Description: Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Description: Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Description: Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
Study: NCT00621218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
Study: NCT03002168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-cyclodextrin
Description: Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
Study: NCT02896686

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Control CT
Description: At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Control CT
Description: At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure.
Study: NCT02269930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: Administered as subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: Administered as subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Administered as subcutaneous injection
Study: NCT02896686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
Study: NCT02269930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Administered as subcutaneous injection
Study: NCT03565380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week community-based multi-model Tai Chi rehabilitation program
Description: Participants will receive 12 x 90 minute sessions of supervised exercises over 12 weeks. In addition to usual care, supervised exercise will be held at the Center of Sports Training and Rehabilitation inside the University and each class will be restricted to no more than 8 participants to ensure sufficient personalized attention. Each training session involves warm-up together with stretching of lower extremity muscles, strengthening exercises of the major lower extremity muscle groups by Theraband, balancing exercise, Tai Chi training, and rest/ cool-down. All lower-extremity exercises will be performed bilaterally.
Study: NCT02896686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinforcement with Light Polypropylene Mesh
Description: Reinforcement with Light Polypropylene Mesh
Study: NCT00387829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraGen Plus Adhesion Barrier Matrix
Description: Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
Study: NCT03565380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual post-operative care
Description: No intervention will be provided
Study: NCT03002168

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active comparator
Study: NCT04151654

Intervention type: OTHER
Group type: OTHER
Intervention: Footwear Assessment Score
Description: It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
Study: NCT01693640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Weekly injections with Abatacept 125 mg over 6 months
Study: NCT01951833

Intervention type: DEVICE
Intervention: EasyOne Pro and Ecomedics
Description: LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics

Intervention type: DEVICE
Intervention: EasyOne Pro and Ecomedics
Description: LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
Study: NCT03487120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet joint denervation
Description: Bipolar electrocautery
Study: NCT02493712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose
Description: 6 capsules of IBD98-M, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose
Description: 4 capsules of IBD98-M

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03006549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergency Manual (Crisis Checklist)
Description: participants will have an Emergency Manual available to them during the crisis simulation scenario.
Study: NCT04816942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Two units of ABO compatible COVID-19 convalescent plasma will be administered.
Study: NCT01607489

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-energy computed tomography investigation
Description: 1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration
Study: NCT01080157

Intervention type: DEVICE
Intervention: SCOUT DS measurement
Description: Non-invasive 3-5 volar forearm scan
Study: NCT01716221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion & Citalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion & Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo & Citalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Placebo
Study: NCT03567811

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submaximal bicycle exercise stress test on Days 1 and 2
Description: Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submaximal bicycle exercise stress test on Days 1 and 2
Description: Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
Study: NCT03095365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Insertion of solid filament needles in the muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Insertion of solid filament needles in the muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
Study: NCT04563845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK3640254
Description: GSK3640254 will be administered.
Study: NCT03002168

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Triolein radiolabeled with 100 microcuries of 3^Hydrogen
Description: A MicroCurie (µCi) is a measure of radioactivity.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Triolein radiolabeled with 100 microcuries of 3^Hydrogen
Description: A MicroCurie (µCi) is a measure of radioactivity.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Description: A MicroCurie (µCi) is a measure of radioactivity.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Description: A MicroCurie (µCi) is a measure of radioactivity.
Study: NCT02984410

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans Oral Surgery (TOS)
Description: TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
Study: NCT01184651

Intervention type: BEHAVIORAL
Intervention: Questionnaires/Interviews
Description: Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .

Intervention type: BEHAVIORAL
Intervention: Questionnaires/Interviews
Description: Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
Study: NCT03125798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure™
Description: LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar electrocautery
Description: Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
Study: NCT02261376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
Study: NCT04563845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT03752814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOSTE Nitinail System
Description: Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
Study: NCT03119779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA-Anglus
Description: MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
Study: NCT02221310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
Study: NCT04262037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
Study: NCT01353378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
Study: NCT04892238

Intervention type: DIAGNOSTIC_TEST
Intervention: 13-C urea breath test
Description: Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive.
Study: NCT02680236

Intervention type: OTHER
Intervention: Art Therapy Group
Description: Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post.
Study: NCT02018991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-Eluting Stent (EES)
Description: Patients treated with EES

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting-Stent (ZES)
Description: Patients treated with ZES
Study: NCT04563845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT02018991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-Eluting-Stent (BES)
Description: Patients treated with BES
Study: NCT00273728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
Description: hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
Study: NCT01325779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: subcutaneous heparin 5000 units every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: subcutaneous enoxaparin 40 milligrams every 24 hours